Identification of predictive biomarkers for treatment outcome in patients with advanced hepatocellular carcinoma
- Conditions
- Diseases of the digestive system
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
? unresectable primary liver cancer
? Age 20 years old or older
? Whole body performance (ECOG) 0-2
? Child-Pugh score is B or more
? Minimum volume of normal liver without tumor invasion> 1000cm3
? Minimum distance between target and organ at risk (eg duodenum, stomach) = 0.5cm
? Adequate *LFT (*AST / *ALT <5 x upper limit of normal, total bilirubin> <3 mg / dl, albumin> 2.5 g / dL, normal *PT / *PTT)
? Adequate renal function (creatinine <1.8 mg / dl or *Ccr> 50 ml / min)
? *BM reserve (*ANC =1500 / mm3, *PLT =50000 / mm3, *Hb> 9 g / dl)
? lesion that can be measured or evaluated on CT
? Those who are pregnant and who agree to contraception
? The person who can read and understand the research agreement and sign the study agreement.
*LFT(liver function test)
*AST(aspartate aminotransferase)
*ALT(alanine Transaminase)
*PT(Prothrombin Time)
*PTT(Partial Thromboplastin Time)
*BM(Bone Marrow)
*ANC(Absolute Neutrophil Count)
*PLT(Platelet count)
*Hb(Hemoglobin)
*Ccr(Creatinine clearance)
? Those who can not perform respiratory training for treatment design
? Patients with a history of previous abdominal radiation therapy
? Those who can not receive consent before treatment
? Those who do not agree to contraception as a pregnant patient
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The association of serum cytokines with pre-selected live markers (usefulness test)
- Secondary Outcome Measures
Name Time Method The relationship between the biomarker selected as the predictive model and the treatment performance (designing the risk prediction model)